Terms: = Ovarian cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
240 results:
1. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of PD-1/pd-l1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract] [Full Text] [Related]
3. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
4. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
5. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
6. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
7. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-pd-l1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Mutch D; Voulgari A; Chen XM; Bradley WH; Oaknin A; Perez Fidalgo JA; Montosa FG; Herraez AC; Holloway RW; Powell MA; Nowicka M; Schaefer G; Merchant M; Yan Y
Cancer; 2024 Jun; 130(11):1940-1951. PubMed ID: 38288862
[TBL] [Abstract] [Full Text] [Related]
8. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
Ling L; Li B; Wu H; Zhang K; Li S; Ke B; Zhu Z; Liu T; Liu P; Zhang B
J Gene Med; 2024 Jan; 26(1):e3606. PubMed ID: 38282157
[TBL] [Abstract] [Full Text] [Related]
9. Uterine Tumors Resembling ovarian Sex Cord Tumors (UTROSCTs): A Scoping Review of 511 Cases, Including 2 New Cases.
Watrowski R; Palumbo M; Guerra S; Gallo A; Zizolfi B; Giampaolino P; Bifulco G; Di Spiezio Sardo A; De Angelis MC
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38276058
[TBL] [Abstract] [Full Text] [Related]
10. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Kim SI; Joung JG; Kim YN; Park J; Park E; Kim JW; Lee S; Lee JB; Kim S; Choi CH; Kim HS; Lim J; Chung J; Kim BG; Lee JY
Gynecol Oncol; 2024 Mar; 182():7-14. PubMed ID: 38246047
[TBL] [Abstract] [Full Text] [Related]
11. Systemic treatment of Patients With Metastatic Breast cancer: ASCO Resource-Stratified Guideline.
Al Sukhun S; Temin S; Barrios CH; Antone NZ; Guerra YC; Chavez-MacGregor M; Chopra R; Danso MA; Gomez HL; Homian NM; Kandil A; Kithaka B; Koczwara B; Moy B; Nakigudde G; Petracci FE; Rugo HS; El Saghir NS; Arun BK
JCO Glob Oncol; 2024 Jan; 10():e2300285. PubMed ID: 38206277
[TBL] [Abstract] [Full Text] [Related]
12. pd-l1 and PD-1 Expression in Early Stage Uterine Endometrioid Carcinoma.
An HJ; Yang JW; Kim MH; Song DH
In Vivo; 2024; 38(1):246-252. PubMed ID: 38148043
[TBL] [Abstract] [Full Text] [Related]
13. Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer.
Kim K; Kim H; Shin I; Noh SJ; Kim JY; Suh KJ; Kim YN; Lee JY; Cho DY; Kim SH; Kim JH; Lee SH; Choi JK
Sci Rep; 2023 Dec; 13(1):22482. PubMed ID: 38110532
[TBL] [Abstract] [Full Text] [Related]
14. Hypoxic 3D Tumor Model for Evaluating of CAR-T Cell Therapy In Vitro.
Oh JM; Shen K
Methods Mol Biol; 2024; 2748():119-134. PubMed ID: 38070112
[TBL] [Abstract] [Full Text] [Related]
15. The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma.
Miceska S; Skof E; Bucek S; Kuhar CG; Gasljevic G; Smrkolj S; Prevodnik VK
Radiol Oncol; 2023 Dec; 57(4):493-506. PubMed ID: 38038414
[TBL] [Abstract] [Full Text] [Related]
16. BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy.
Farokhi Boroujeni S; Rodriguez G; Galpin K; Yakubovich E; Murshed H; Ibrahim D; Asif S; Vanderhyden BC
J Ovarian Res; 2023 Nov; 16(1):231. PubMed ID: 38017453
[TBL] [Abstract] [Full Text] [Related]
17. Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αpdl1 in ovarian cancer.
Wang S; Liu Y; Xiao H; Chen Z; Yang X; Yin J; Li Y; Yuan C; Yan S; Chen G; Gao Q; Kong B; Sun C; Song K
Cell Death Dis; 2023 Nov; 14(11):775. PubMed ID: 38012150
[TBL] [Abstract] [Full Text] [Related]
18. Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer.
Kim T; Lim H; Jun S; Park J; Lee D; Lee JH; Lee JY; Bang D
Sci Rep; 2023 Nov; 13(1):20485. PubMed ID: 37993659
[TBL] [Abstract] [Full Text] [Related]
19. Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer.
Cook DP; Galpin KJC; Rodriguez GM; Shakfa N; Wilson-Sanchez J; Echaibi M; Pereira M; Matuszewska K; Haagsma J; Murshed H; Cudmore AO; MacDonald E; Tone A; Shepherd TG; Petrik JJ; Koti M; Vanderhyden BC
Commun Biol; 2023 Nov; 6(1):1152. PubMed ID: 37957414
[TBL] [Abstract] [Full Text] [Related]
20. Expression of EGFR, pd-l1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
[Next]
